BIOMAT Database Logo BIOMAT Database Logo

Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. 2020

Abby S Van Voorhees, and Linda Stein Gold, and Mark Lebwohl, and Bruce Strober, and Charles Lynde, and Stephen Tyring, and Ashley Cauthen, and Howard Sofen, and Zuoshun Zhang, and Maria Paris, and Yao Wang
Eastern Virginia Medical School, Norfolk, Virginia. Electronic address: vanvooas@evms.edu.

BACKGROUND Many patients with psoriasis are bothered by symptoms in highly visible, pruritic areas, such as the scalp. OBJECTIVE To evaluate the efficacy and safety of apremilast for moderate to severe scalp psoriasis. METHODS This phase 3b, double-blind, placebo-controlled study randomized adults with moderate to severe scalp psoriasis who had inadequate response/intolerance to at least 1 topical scalp psoriasis therapy (NCT03123471). The primary endpoint was the proportion of patients who achieved Scalp Physician Global Assessment response, defined as score of 0 (clear) or 1 (almost clear), with at least a 2-point reduction, at week 16. Secondary endpoints included at least a 4-point improvement from baseline in Whole Body Itch and Scalp Itch Numeric Rating Scales (NRSs) and mean improvement in Dermatology Life Quality Index (DLQI) at week 16. RESULTS There were 303 randomized patients (placebo: n = 102; apremilast: n = 201). With apremilast, significantly more patients achieved Scalp Physician Global Assessment (43.3% vs 13.7%), Scalp Itch NRS (47.1% vs 21.1%), and Whole Body Itch NRS (45.5% vs 22.5%) response, and significantly greater DLQI improvement was observed versus placebo (-6.7 vs -3.8; all P < .0001). Common adverse events with apremilast were diarrhea (30.5%), nausea (21.5%), headache (12.0%), and vomiting (5.5%). CONCLUSIONS Patients with mild disease were not enrolled. CONCLUSIONS Apremilast showed efficacy for the treatment of moderate to severe scalp psoriasis.

UI MeSH Term Description Entries
D008297 Male Males
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents
D012536 Scalp Dermatoses Skin diseases involving the SCALP. Scalp Dermatosis,Dermatoses, Scalp,Dermatosis, Scalp

Related Publications

Abby S Van Voorhees, and Linda Stein Gold, and Mark Lebwohl, and Bruce Strober, and Charles Lynde, and Stephen Tyring, and Ashley Cauthen, and Howard Sofen, and Zuoshun Zhang, and Maria Paris, and Yao Wang
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study.
March 2024, Journal of the American Academy of Dermatology,
Abby S Van Voorhees, and Linda Stein Gold, and Mark Lebwohl, and Bruce Strober, and Charles Lynde, and Stephen Tyring, and Ashley Cauthen, and Howard Sofen, and Zuoshun Zhang, and Maria Paris, and Yao Wang
Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
January 2022, Journal of the American Academy of Dermatology,
Abby S Van Voorhees, and Linda Stein Gold, and Mark Lebwohl, and Bruce Strober, and Charles Lynde, and Stephen Tyring, and Ashley Cauthen, and Howard Sofen, and Zuoshun Zhang, and Maria Paris, and Yao Wang
Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
March 2013, Journal of the European Academy of Dermatology and Venereology : JEADV,
Abby S Van Voorhees, and Linda Stein Gold, and Mark Lebwohl, and Bruce Strober, and Charles Lynde, and Stephen Tyring, and Ashley Cauthen, and Howard Sofen, and Zuoshun Zhang, and Maria Paris, and Yao Wang
Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial.
October 2023, Journal of the American Academy of Dermatology,
Abby S Van Voorhees, and Linda Stein Gold, and Mark Lebwohl, and Bruce Strober, and Charles Lynde, and Stephen Tyring, and Ashley Cauthen, and Howard Sofen, and Zuoshun Zhang, and Maria Paris, and Yao Wang
Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study.
January 2017, Journal of the European Academy of Dermatology and Venereology : JEADV,
Abby S Van Voorhees, and Linda Stein Gold, and Mark Lebwohl, and Bruce Strober, and Charles Lynde, and Stephen Tyring, and Ashley Cauthen, and Howard Sofen, and Zuoshun Zhang, and Maria Paris, and Yao Wang
Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept.
July 2012, Journal of the American Academy of Dermatology,
Abby S Van Voorhees, and Linda Stein Gold, and Mark Lebwohl, and Bruce Strober, and Charles Lynde, and Stephen Tyring, and Ashley Cauthen, and Howard Sofen, and Zuoshun Zhang, and Maria Paris, and Yao Wang
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.
October 2017, Journal of the American Academy of Dermatology,
Abby S Van Voorhees, and Linda Stein Gold, and Mark Lebwohl, and Bruce Strober, and Charles Lynde, and Stephen Tyring, and Ashley Cauthen, and Howard Sofen, and Zuoshun Zhang, and Maria Paris, and Yao Wang
The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study.
October 2017, Journal of dermatological science,
Abby S Van Voorhees, and Linda Stein Gold, and Mark Lebwohl, and Bruce Strober, and Charles Lynde, and Stephen Tyring, and Ashley Cauthen, and Howard Sofen, and Zuoshun Zhang, and Maria Paris, and Yao Wang
A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.
February 2024, The British journal of dermatology,
Abby S Van Voorhees, and Linda Stein Gold, and Mark Lebwohl, and Bruce Strober, and Charles Lynde, and Stephen Tyring, and Ashley Cauthen, and Howard Sofen, and Zuoshun Zhang, and Maria Paris, and Yao Wang
Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.
March 2018, Journal of the European Academy of Dermatology and Venereology : JEADV,
Copied contents to your clipboard!